Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate.

Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate.

Antibody drug conjugates (ADCs) are no longer an unknown entity in the field of cancer therapy with the success of marketed ADCs like ADCETRIS and KADCYLA and numerous others advancing through clinical trials. The pursuit of novel cytotoxic payloads beyond the mictotubule inhibitors and DNA damaging...

Full description

Bibliographic Details
Main Authors: Sujiet Puthenveetil, Haiyin He, Frank Loganzo, Sylvia Musto, Jesse Teske, Michael Green, Xingzhi Tan, Christine Hosselet, Judy Lucas, L Nathan Tumey, Puja Sapra, Chakrapani Subramanyam, Christopher J O'Donnell, Edmund I Graziani
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5448779?pdf=render

Internet

http://europepmc.org/articles/PMC5448779?pdf=render

Similar Items